Track Cognition Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cognition Therapeutics Inc. Common Stock CGTX · Stock Open Cognition Therapeutics Inc. Common Stock in new tab

0.6798 USD
EPS
-0.16
P/B
2.21
ROE
-48.60
Beta
1.80
Target Price
3.33 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
EPS-0.16
Book Value0.31
Price to Book2.21
Debt/Equity1.67
% Insiders1.298%
Estimates
Forward P/E-3.67
Forward EPS-0.19
Target Mean Price3.33

DCF valuation

Model fair value for Cognition Therapeutics Inc. Common Stock (CGTX)
Result
Sign in to run the valuation for CGTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Strong buy · mean target 3.33 USD (low 3.00, high 4.00) · as of 15 Nov 2026
Low 3.00
Mean 3.33
High 4.00
Price 0.6798
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cognition Therapeutics Inc. Common Stock Logo Cognition Therapeutics Inc. Common Stock Analysis (CGTX)

United States Health Care Official Website Stock

Is Cognition Therapeutics Inc. Common Stock a good investment? Cognition Therapeutics Inc. Common Stock (CGTX) is currently trading at 0.6798 USD. Market analysts have a consensus price target of 3.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cognition Therapeutics Inc. Common Stock is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -0.19.

Investor FAQ

Does Cognition Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cognition Therapeutics Inc. Common Stock?

Cognition Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -0.16.

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Exchange Ticker
NMS (United States) CGTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion